Market reviews 2019

Published on 5 February 2020

Finland is the most important individual market for Orion, generating about one-third of the Group's net sales. According to Pharmarket 2019 statistics, the total sales of Orion's human pharmaceuticals, including both medicinal and non-medicinal products, was behind market trend. The growth in the Finnish pharmaceuticals market has mostly been generated by proprietary products, while they only account for a small share of Orion's net sales in Finland.

Orion's biggest product group in Finland are reference-priced prescription drugs in the pharmacy channel. The sales of Orion's reference-priced prescription drugs declined from the comparative period due to continuing tough price competition and availability disruptions. However, sales volume still continued to increase, albeit slightly more slowly than the market. The average price of reference-priced drugs in the market declined in 2019 by approximately 8% from the comparative period (Source: Pharmarket). The impact of price competition on Orion has been significant due to the Company's broad product range and significant market share in Finland.

Despite the challenging operating environment, Orion has maintained its position as leader in marketing pharmaceuticals in Finland. Orion has a particularly strong position in reference priced prescription drugs and in self-care product sales, with its market share being a quarter of the market in each.

Sales of human pharmaceuticals in Finland (medicinal and non-medicinal products):

EUR million

 

1-12/19

1-12/18

Change %

Total sales of human pharmaceuticals (hospital and pharmacy channel)

 

 

 

Market

 

2,859

2,715

+5%

Orion

 

314

314

-0%

Prescription drugs total (pharmacy channel)

 

 

 

 

Market

1,602

1,533

+4%

Orion

178

183

-3%

Reference priced prescription drugs (pharmacy channel)

 

 

 

Market

436

455

-4% 

Orion

116

123

-6% 

Self-care products (pharmacy channel)

 

 

 

Market

 

399

389

+2% 

Orion

 

100

96

+5% 

             

 

Source: Pharmarket sales statistics 1-12/2019

 

Orion's market share in the sales of human pharmaceuticals in Finland (medicinal and non-medicinal products):

Orion's market share, %

1-12/19

1-12/18

Human pharmaceuticals in total (hospital and pharmacy channel)

11%

12%

Prescription drugs total (pharmacy channel)

11%

12%

Reference priced prescription drugs (pharmacy channel)

27%

27%

Self-care products (pharmacy channel)

25%

25%


Source: Pharmarket sales statistics 1-12/2019

 

Orion is a significant player also in the Scandinavian generics market.

 

According to IQVIA pharmaceutical sales statistics, in Europe total sales of the most common intravenous anaesthetics and intensive care sedatives (propofol, midazolam, remifentanil and dexmedetomidine) in the 12-month period ending in September 2019 were up by 4% at EUR 595 (570) million. The active ingredient in  Orion’s Dexdor® intensive care sedative is dexmedetomidine. The total sales of dexmedetomidine  wasEUR 72 (69) million in Europe, according to IQVIA pharmaceutical sales statistics..

Published on 23 October 2019

Finland is the most important individual market for Orion, generating about one-third of the Group's net sales. According to Pharmarket statistics (1-9/2019), the total sales of Orion's human pharmaceuticals, including both medicinal and non-medicinal products, was behind market trend. The growth in the Finnish pharmaceuticals market has mostly been generated by proprietary products, while they only account for a small share of Orion's net sales in Finland.

Orion's biggest product group in Finland are reference-priced prescription drugs in the pharmacy channel. The sales volume of Orion's reference priced prescription drugs developed slightly better than the market, but in euros sales declined from the comparative period due to continuing tough price competition and availability disruptions. The average price of reference priced drugs in the market declined in January–September 2019 by approximately 10% from the comparative period (Source: Pharmarket). The impact of price competition on Orion has been significant due to the Company's broad product range and significant market share in Finland.

Despite the challenging operating environment, Orion has maintained its position as leader in marketing pharmaceuticals in Finland. Orion has a particularly strong position in reference priced prescription drugs and in self-care product sales, with its market share being a quarter of the market in each.

Sales of human pharmaceuticals in Finland (medicinal and non-medicinal products):

EUR million

 

1-9/19

1-9/18

Change %

Total sales of human pharmaceuticals (hospital and pharmacy channel)

 

 

 

Market

 

2,083

1,977

+5%

Orion

 

229

230

-0%

Prescription drugs total (pharmacy channel)

 

 

 

 

Market

1,157

1,108

+4%

Orion

129

133

-3%

Reference priced prescription drugs (pharmacy channel)

 

 

 

Market

319

342

-7% 

Orion

85

90

-5% 

Self-care products (pharmacy channel)

 

 

 

Market

 

296

290

+2% 

Orion

 

73

71

+4% 

             

Source: Pharmarket sales statistics 1-9/2019

Orion's market share in the sales of human pharmaceuticals in Finland (medicinal and non-medicinal products):

 

Orion's market share, %

1-9/19

1-9/18

Human pharmaceuticals in total (hospital and pharmacy channel)

11%

12%

Prescription drugs total (pharmacy channel)

11%

12%

Reference priced prescription drugs (pharmacy channel)

27%

26%

Self-care products (pharmacy channel)

25%

24%

Source: Pharmarket sales statistics 1-9/2019

Orion is a significant player also in the Scandinavian generics market.

According to IQVIA pharmaceutical sales statistics, in Europe total sales of the most common intravenous anaesthetics and intensive care sedatives (propofol, midazolam, remifentanil and dexmedetomidine) in the 12-month period ending in June 2019 were up by 4% at EUR 585 (563) million. Sales of Orion’s Dexdor® intensive care sedative (dexmedetomidine) totalled EUR 72 (68) million in Europe, according to IQVIA pharmaceutical sales statistics.

 

Review of human pharmaceuticals market

Published on 17 July 2019

Finland is the most important individual market for Orion, generating about one-third of the Group’s net sales. According to Pharmarket statistics (1-6/2019), the total sales of Orion’s human pharmaceuticals, including both medicinal and non-medicinal products, was behind market trend. The growth in the Finnish pharmaceuticals market has mostly been generated by proprietary products, while they only account for a small share of Orion’s net sales in Finland.

Orion’s biggest product group in Finland are reference-priced prescription drugs in the pharmacy channel. The sales volume of Orion’s reference-priced prescription drugs developed slightly better than the market, but in euros sales declined from the comparative period due to continuing price competition. The average price of reference priced drugs in the market declined in January–June 2019 by approximately 10% from the comparative period (Source: Pharmarket). The impact of price competition on Orion has been significant due to the Company’s broad product range and significant market share in Finland.

Despite the challenging operating environment, Orion has maintained its position as leader in marketing pharmaceuticals in Finland. Orion has a particularly strong position in reference priced prescription drugs and in self-care product sales, with its market share being a quarter of the market in each.

Sales of human pharmaceuticals in Finland (medicinal and non-medicinal products):

EUR million                

 

1-6/2019

1-6/2018

Change %

Total sales of human pharmaceuticals (hospital and pharmacy channel)

       
Market   1,376 1,320 +4%
Orion   151 155 -2%
Prescription drugs total (pharmacy channel)        
Market   732 754 +3%
Orion   85 89 -4%
Reference priced prescription drugs (pharmacy channel)        
Market   216 235 -8%
Orion   56 60  -7%
Self-care products (pharmacy channel)        
Market   197 197 +0%
Orion   48 47 +1%
 

Source: Pharmarket sales statistics 1-6/2019

 

Orion’s market share in the sales of human pharmaceuticals in Finland (medicinal and non-medicinal products):

Orion's market share, %

 

1-6/2019

1-6/2018

Human pharmaceuticals in total (hospital and pharmacy channel)   11% 12%
Prescription drugs total (pharmacy channel)   12% 12%
Reference priced prescription drugs (pharmacy channel)   26% 26%
Self-care products (pharmacy channel)   24% 24%

Source: Pharmarket sales statistics 1-6/2019

 

Orion is a significant player also in the Scandinavian generics market.

According to IQVIA pharmaceutical sales statistics, in Europe total sales of the most common intravenous anaesthetics and intensive care sedatives (propofol, midazolam, remifentanil and dexmedetomidine) in the 12-month period ending in March 2019 were up by 3% at EUR 574 (555) million. Sales of Orion’s Dexdor® intensive care sedative (dexmedetomidine) totalled EUR 64 (64) million in Europe, according to IQVIA pharmaceutical sales statistics.

 

***

Market review on human pharmaceuticals

Published on 25 April 2019

Finland is the most important individual market for Orion, generating about one-third of the Group’s net sales. According to Pharmarket statistics (1–3/2019), the share of reference priced drugs of Orion’s prescription drug sales in the Finnish pharmacy channel was approximately 67% (Source: Pharmarket). The sales volume of Orion’s reference priced prescription drugs developed slightly better than the market, but in euros sales declined from the comparative period due to continuing price competition. The average price of reference priced drugs in the market decreased in January–March 2019 by approximately 10% from the comparative period (Source: Pharmarket). The impact of price competition on Orion has been significant due to the Company’s broad product range and significant market share in Finland. The total sales of Orion’s human pharmaceuticals, including both medicinal and non-medicinal products, was behind market trend. The growth in the Finnish pharmaceuticals market has mostly been generated by proprietary products, while they only account for a small share of Orion’s net sales in Finland.

Sales of human pharmaceuticals in Finland (medicinal and non-medicinal products):

EUR million          

 

1-3/2019

1-3/2018

Change %

Reference priced prescription drugs (pharmacy)

       
Market   106 118 -10%
Orion   28 30 -7%
Self-care (pharmacy)
       
Market   103 104 -1%
Orion   25 25 -1%
Total human pharmaceuticals sales
(hospital, pharmacy)
       
Market   676 647 +4%
Orion   76 79 -4%

Source: Pharmarket sales statistics 1-3/2019

Despite the challenging operating environment, Orion has maintained its position as leader in marketing pharmaceuticals in Finland. Orion has a particularly strong position in reference priced prescription drugs and in self-care product sales, with its market share being a quarter of the market in each.

Orion’s market share in the sales of human pharmaceuticals in Finland (medicinal and non-medicinal products):

milj. EUR tai USD

 

1-3/2019

1-3/2018

Reference priced prescription drugs (pharmacy)   26% 26%
Self-care (pharmacy)   24% 24%
Human pharmaceuticals total (pharmacy, hospital)   11% 12%

Source: Pharmarket sales statistics 1-3/2019

 

Orion is a significant player also in the Scandinavian generic drugs market.

The treatment of Parkinson’s disease continues to be an important therapy area for Orion. In January–March 2019, Orion’s branded Parkinson’s drugs containing entacapone (Stalevo®, Comtess® and Comtan®) accounted for 9% (11%) of the Group’s net sales.

Total sales of Orion’s branded Parkinson’s drugs:

EUR/USD million

 

MAT12/2018

MAT12/2017

Change %

USA

USD

4 6 -29%

Europe TOP 5

EUR

40 52 -23%

Japan

EUR

66 73 -10%

Source: IQVIA pharmaceutical sales statistics MAT12/2018
Europe TOP 5: Germany, United Kingdom, France, Spain and Italy

 

According to IQVIA pharmaceutical sales statistics, in Europe total sales of the most common intravenous anaesthetics and intensive care sedatives (propofol, midazolam, remifentanil and dexmedetomidine) in the 12-month period ending in December 2018 were up by 5% at EUR 569 (542) million. Sales of Orion’s Dexdor® intensive care sedative (dexmedetomidine) totalled EUR 64 (64) million (+0%) in Europe, according to IQVIA pharmaceutical sales statistics.

 

***